Deals Of The Week: Ikaria/Fibrex, AstraZeneca/Forest, Forest/Nycomed ...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Forest Continues To Bank On Growth Of its Savella Medication for Fibromyalgia
With the only drug indicated solely for fibromyalgia, Forest expects Savella to help offset declining sales from its Lexapro antidepressant.
Forest Continues To Bank On Growth Of its Savella Medication for Fibromyalgia
With the only drug indicated solely for fibromyalgia, Forest expects Savella to help offset declining sales from its Lexapro antidepressant.
With Second Licensing Deal In A Month, Ikaria Adds To Critical Care Pipeline
Deal with Fibrex Medical brings Ikaria a Phase II cardiology drug plus two preclinical compounds.